April 2004
Gut;Apr2004 Supplement 3, Vol. 53, pA83
Academic Journal
Non-alcoholic fatty liver disease (NAFLD} is a disease of emerging importance. It is associated with the metabolic syndrome comprising obesity, insulin resistance, hyperlipidaemia and hypertension. The pathophysiology involves two steps: insulin resistance causing steatosis followed by oxidative stress, which produces lipid peroxidation and activation of inflammatory cytokines resulting in steatohepotitis. Non-alcoholic steatohepotitis (NASH) is associated with fibrosis in 15-50% of patients. The aim is to determine prevalence of the components of the metabolic syndrome in our white patient cohort with biopsy proven NASH.


Related Articles

  • The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Qing Liu; Stig Bengmark; Shen Qu // Lipids in Health & Disease;2010, Vol. 9, p42 

    Nonalcoholic fatty liver disease is increasingly regarded as a hepatic manifestation of metabolic syndrome, and the severity of nonalcoholic fatty liver disease seems to increase in parallel with other features of metabolic syndrome. Excess lipid accumulation in the liver cells is not only a...

  • Current Treatment Strategies for Non-Alcoholic Fatty Liver Disease (NAFLD). Poonam Mishra; Zobair M. Younossi // Current Drug Discovery Technologies;Sep2007, Vol. 4 Issue 2, p133 

    Nonalcoholic fatty liver disease (NAFLD) is recognized as the most common cause of chronic liver disease worldwide. NAFLD is a clinicopathologic syndrome ranging from simple steatosis, which is relatively benign, to the more severe form known as nonalcoholic steatohepatitis (NASH), which may...

  • Thiazolidinediones. Yki-J√§rvinen, Hannele // New England Journal of Medicine;9/9/2004, Vol. 351 Issue 11, p1106 

    Presents a review article on the use of thiazolidinediones which are the first drugs to address insulin resistance in the treatment of diabetes. Belief of the author that this class of drugs may also have a role in treating patients with nondiabetic insulin-resistant conditions; The superfamily...

  • Increased Circulating Betatrophin Concentrations in Patients with Type 2 Diabetes. Espes, Daniel; Martinell, Mats; Carlsson, Per-Ola // International Journal of Endocrinology;2014, p1 

    Betatrophin has recently been described as a key hormone to stimulate beta-cell mass expansion in response to insulin resistance and obesity in mice. The finding has generated an interest in the development of antidiabetic drugs with betatrophin as the active component. However, the circulating...

  • NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease. Enjoji, Munechika; Machida, Kazuyuki; Kohjima, Motoyuki; Kato, Masaki; Kotoh, Kazuhiro; Matsunaga, Kazuhisa; Nakashima, Manabu; Nakamuta, Makoto // Lipids in Health & Disease;2010, Vol. 9, p29 

    Background: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of...

  • Maternal Immunization Affects In Utero Programming of Insulin Resistance and Type 2 Diabetes. Eberle, Claudia; Merki, Esther; Yamashita, Tomoya; Johnson, Susie; Armando, Aaron M.; Quehenberger, Oswald; Napoli, Claudio; Palinski, Wulf; Zenclussen, Ana Claudia // PLoS ONE;Sep2012, Vol. 7 Issue 9, Special section p1 

    Maternal immunization with oxidized lipoproteins prior to pregnancy protects against atherogenic in utero programming by gestational hypercholesterolemia and enhances beneficial lymphocyte-dependent immune responses in offspring. To determine whether in utero programming and immunomodulation...

  • Non-alcoholic fatty liver disease and the metabolic syndrome: An update. Rector, R. Scott; Thyfault, John P.; Yongzhong Wei; Ibdah, Jamal A. // World Journal of Gastroenterology;1/14/2008, Vol. 14 Issue 2, p185 

    Sedentary lifestyle and poor dietary choices are leading to a weight gain epidemic in westernized countries, subsequently increasing the risk for developing the metabolic syndrome and nonalcoholic fatty liver disease (NAFLD). NAFLD is estimated to affect approximate 30% of the general US...

  • Diabetes and Nonalcoholic Fatty Liver Disease. Kantartzis, Konstantinos; Gastaldelli, Amalia; Magkos, Faidon; Lavoie, Jean-Marc // Experimental Diabetes Research;2012, Special section p1 

    The article discusses papers within the January 2012 issue of "Experimental Diabetes Research," including a paper on diagnosis and evaluation of nonalcoholic fatty liver disease, a paper on the role of transcription factor modifications in the pathogenesis of insulin resistance, and a paper on...

  • Increased Expression and Activity of the Transcription Factor FOXO1 in Nonalcoholic Steatohepatitis. Valenti, Luca; Rametta, Raffaela; Dongiovanni, Paola; Maggioni, Marco; Fracanzani, Anna Ludovica; Zappa, Marco; Lattuada, Enzo; Roviaro, Giancarlo; Fargion, Silvia // Diabetes;May2008, Vol. 57 Issue 5, p1355 

    OBJECTIVE--Nonalcoholic fatty liver, affecting 34% of the U.S. population, is characterized by hepatic insulin resistance, which is more marked in the presence of steatohepatitis, and frequently precedes hyperglycemia. The molecular mechanisms underlying the relationship between fatty liver and...


Read the Article


Sign out of this library

Other Topics